Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number 001-41940 Autonomix Medical, Inc. (Exact Name of Registrant as Specified in Its Charter) Delawar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock, par value $0.001 per share AMIX The Nasdaq Stock Market LLC FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Autonomix Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41940 47-1607810 (State or other ...

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. About Autonomix Medical, Inc. For more information, visit autonomix.com and connect with the Company on ...

Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Of ...

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDAcleared ablation technology from RF Innovations, Inc. For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. Ab ...

For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pa ...

Core Viewpoint - Autonomix Medical (NASDAQ:AMIX) experienced significant stock volatility, with a notable rally followed by a decline in share price due to market reactions and company announcements [1][6]. Group 1: Stock Performance - AMIX stock rallied 130% during normal trading hours yesterday, with approximately 152 million shares traded, significantly above its daily average of about 3 million shares [5]. - Following the rally, AMIX stock is down 16.7% as of Tuesday morning, indicating a correction after the previous day's gains [6]. Group 2: Company Developments - Autonomix Medical announced a definitive agreement with RF Innovations to license the intellectual property of its Apex 6 Radiofrequency Generator, expected to be completed by the end of the month [2]. - The company provided updates on its pancreatic cancer pain management device, reporting positive results from a clinical trial that utilizes radiofrequency (RF) ablation to alleviate pain in pancreatic cancer patients [4].

Per the release, Autonomix intends to leverage the technology in its strategic therapeutic units to enhance value for its pipeline. "This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management," stated President and CEO Brad Hauser. At the same time, Autonomix is a speculative enterprise. The company made its public ...